Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis

참고문헌 (9)

1. Ik Hyun Jo, "Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year", Gut and Liver (2021), The Editorial Office of Gut and Liver[DOI]
2. Ronald Keller, "Quality of life in inflammatory bowel diseases: it is not all about the bowel", Intestinal research, 19(1), pp.45~52 (2021), 대한장연구학회[DOI]
3. Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
4. Turner D, "STRIDE-II : an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)initiative of the International Organization for the Study of IBD(IOIBD) : determining therapeutic goals for treat-to-target strategies in IBD", Gastroenterology, 160, pp.1570~1583 (2021)
5. Shin Ju-Young, "Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study", Gut and Liver, 15(6), pp.867~877 (2021), 거트앤리버 소화기연관학회협의회[DOI]
6. Reich KM, "The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use : a time-trend study", Aliment Pharmacol Ther, 40, pp.629~638 (2014)
7. Jenkinson PW, "Analysis of colectomy rates for ulcerative colitis in pre-and postbiological eras in Lothian, Scotland", Colorectal Dis, 23, pp.1175~1183 (2021)
8. "2020 Inflammatory bowel disease fact sheet in Korea" (2009)[URL]
9. Kane S, "Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis", Am J Med, 114, pp.39~43 (2003)

관련 논문AI추천